Wet AMD 5 Symposium

Related

• 

  Are There Safety Concerns With Bevacizumab for ROP

  Robert L. Avery, MD

  Updates from the Field

  2017

• 

  Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study

  W. Lloyd Clark, MD, FASRS

  Updates from the Field

  2022

• 

  Port Delivery System With Ranibizumab: Key Outcomes From the Ladder Phase 2 Trial That Supported Archway Phase 3 Study Design

  Arshad M. Khanani, MD, MA, FASRS

  Annual Meeting Talks

  2019